Trial Profile

Therapeutic drug monitoring for oral anti-cancer drugs

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Antineoplastics (Primary) ; Enzalutamide (Primary) ; Imatinib (Primary) ; Pazopanib (Primary) ; Trametinib (Primary)
Indications Cancer; Renal cell carcinoma; Soft tissue sarcoma
Focus Pharmacokinetics; Therapeutic Use

Most Recent Events

31 May 2020 Results (n=34) from patients receiving Pazopanib, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
12 Mar 2020 Results assessing dosing and PK characteristics of Abiraterone treatment published in the European Journal of Cancer
13 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com